Table 1.

Statements from the literature for semi-structured interview guideline.

“Manufacturers sometimes set research priorities on the basis of the pursuit of a research hypothesis, as opposed to developing new technologies that meet unmet social need” (Drummond et al., 2013)

“Resources for development of new technologies can be used much more effectively if industry and HTA agencies were to collaborate at an early stage in the development process” (Jöhnsson, 2015)

“The main actors in the health care sector have different perspectives on the value added by health technologies” (Drummond et al., 2013)

“Manufacturers feel that the restrictions on the use and price of health technologies resulting from HTAs limits their sales potential and ultimately the profits from which future research has to be funded” (Drummond et al., 2013)

“It has been discussed if the QALY fully captures the benefits of new cancer drugs. The higher cost per QALY criteria for oncology drugs may reflect a view that there may be an additional benefit or value of treatment that should be considered” (Jönsson, 2013)

“The question how to define justifiable prices for oncology drugs needs to be addressed. Currently, prices are often set in relation to international standards and investments of manufacturers” (Fibig, 2013)

“Value-based pricing is likely to give manufacturers an incentive to more closely align their R&D with social objectives” (Fibig, 2013)

“If all elements of value are considered and taken into account in decision making, there is a risk that higher prices will be the result” (Fibig, 2013)